Details
Category: Volume 05 Issue 09 September 2017
Hits: 2166

Title: Study of Serum Soluble Klotho in Egyptian Hemodialysis Patients

Authors: Hesham K H Keryakos, Hisham Abdel Haleem Ali, Aml Kamal Helmy, Mostafa Ahmed El-Sayed Abu-El-Ela, Moustafa A. Kader A. Wahab, TamerTaha Ismail, Sherif R Abd Al-Razek

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i9.35

Abstract

Preclinical studies demonstrated that klotho has cardio protective effect. One important biological function of Klotho is to maintain mineral homeostasis, which is both fibro blast growth factor-23 (FGF23)-dependent and FGF23-independent.

Aims: to study the relation between serum soluble klotho (sKlotho) and the following cardiovascular parameters; valvular calcification, vascular calcification, pulmonary hypertension (PH) and left ventricular hypertrophy (LVH). Also, we studied the relation between sklotho andbone mineral density (BMD) as well as serum ferritin.

Methods: 40 hemodialysis (HD) patients were recruited from Minia University Hospital dialysis center as well as 20 healthy controls participated in this study. sklotho,  FGF-23, sclerostin, 25-OH-D, iPTH, and ferrit in were measured. High resolution peripheral quantitative computed tomography (HR-pQCT) was used to measure BMD. Multi-detector computed tomography (MDCT) was used to detect aortic calcification. Transthoracic echocardiography was used to detect LVH, PH, and valvular calcifications.

Results: sklotho level was significantly lower in HD patients than controls. In significant deffirences in sklotho levels between patients with and without PH and between patients with and without LVH. However, patients with higher sklotho had a trend toward protection from valvular and vascular calcification. There was a positive correlation between sklotho and  25-OH- D (r = 0.359, p = 0.023), and serum corrected total calcium (r = 0.956, p < 0.001). Mean while, there was a negative correlation between sklotho and BMD (r = -0.425, p = 0.006), FGF-23 (r = -0.375, p = 0.017),  sclerostin (r = -0.445, p = 0.004), phosphorus (r = -0.859, p< 0.001). We found also that sklothois negatively correlated with serum ferritin in healthy controls and this correlation was disrupted in HD patients.

Conclusions: Higher sklotho was associated with decreased BMD, and a trend toward absence ofaortic and valvular calcifications in HD patients.

Keywords: sklotho, PH, LVH, aortic and valvular calcifications, BMD.

 

References

  1. Kuro OM, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature.1997, 390: 45-51.
  2. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T, Nabeshima Y: Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett. 2004, 565: 143-147.
  3. Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y: Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun. 1998, 242: 626-630.
  4. Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG: The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science. 2005, 310: 490-493.
  5. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, Razzaque MS, Rosenblatt KP, Baum MG, Kuro-o M, Moe OW: Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 2010, 24: 3438-3450.
  6. Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wuthrich RP, Russmann S, Serra AL: Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectionalstudy. Nephrol Dial Transplant. 2013, 28: 352-359.
  7. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro- OM, Moe OW: Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011, 22: 124-136.
  8. Seiler S, Wen M, Roth HJ, Fehrenz M, Flugge F, Herath E, Weihrauch A, Fliser D, Heine GH: Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int. 2013, 83: 121-128.
  9. Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H, Miyoshi M, Ogawa Y, Castrillon DH, Rosenblatt KP, Kuro-o M: Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem. 2005, 280: 38029-38034.
  10. Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, Hsiao LL: Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation. 2012, 125: 2243-2255.
  11. Hu MC, Shiizaki K, Kuro-o M, Moe OW: Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013, 75: 503-533.
  12. Lindberg K, Amin R, Moe OW, Hu MC, Erben RG, Ostman WA, Lanske B, Olauson H, Larsson TE: The kidney is the principal organ mediating klotho effects. J Am Soc Nephrol. 2014, 25: 2169-2175.
  13. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol.2011,22: 124–136.
  14. Akimoto T., Kimura T., Watanabe Y. et al., The impact of nephrectomy and renal transplantation on serum levels of soluble Klotho protein. Transplantation Proceedings. 2013; 45: 134–136.
  15. Hu MC, Shi M, Zhang J et al., Renal production, uptake, and handling of circulating 𝛼 J Am Soc Nephrol. 2016; 27(1):79-90.
  16. Naoko OT, Takahiro M, Tetsu A, Sumiko H, Yuko W, Kazuhiro S, Takuya M, Eiji K, Yasushi A, Makoto K, and Daisuke N. Association between Serum Soluble Klotho Levels and Mortality in Chronic Hemodia-lysis Patients. International Journal of Endocrinology 2015, Article ID 406269, 10 pages
  17. Sise ME, Courtwright AM and Channick RN. Pulmonary hypertension in patients with chronic and end-stage kidney disease Kidney International (2013) 84, 682–692.
  18. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393–4408
  19. Abdallah E, Mosbah O, Khalifa G, Metwaly A, El-Bendary O. Assessment of the relationship between serum soluble Klotho and carotid intimaemedia thickness and left ventricular dysfunction in hemodialysis patients Kidney Res Clin Pract 2016; 35:42-49
  20. Sakan H, Nakatani K, Asai O, Imura A, Tanaka T, Yoshimoto S, Iwamoto N, Kurumatani N, Iwano M, Nabeshima Y, Konishi N, Saito Y. Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS One. 2014. 23;9(1):e 86301.
  21. Paccou J, Mentaverri R, Renard C, Liabeuf S, Fardellone P, Massy ZA, Brazier M, Kamel S. The relationships between serum sclerostin, bone mineral density, and vascular calcification in rheumatoid arthritis. J Clin Endocrinol Metab. 2014; 99(12):4740-4748.
  22. Sawires HK, Essam RM, Morgan MF, Mahmoud RA: Serum klotho: relation to fibroblast growth factor-23 and other regulators of phosphate metabolism in children with chronic kidney disease. Nephron.2015, 129:293-299.

Corresponding Author

Hesham K H Keryakos

Division of Nephrology, Department of Internal Medicine,

Faculty of Medicine, Minia, Egypt

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.